A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
Author:
Affiliation:
1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas
2. Department of Symptom Research; The University of Texas MD Anderson Cancer Center; Houston Texas
Funder
Ariad Pharmaceuticals
University of Texas MD Anderson Cancer Center
Bristol-Myers Squibb
Novartis Pharma
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1808/fullpdf
Reference30 articles.
1. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia;Cortes;J Clin Oncol,2010
2. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood,2012
3. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;New Engl J Med,2010
4. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol,2015
5. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;New Engl J Med,2010
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation;Biomarker Research;2024-05-04
2. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05
3. Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-01-03
4. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives;European Journal of Oncology Nursing;2023-12
5. Chronic Myeloid Leukaemia: A Qualitative Study of Patient and Practitioner Experiences of Managing Treatment;European Journal of Cancer Care;2023-11-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3